We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

154 hedge funds and large institutions have $1.18B invested in Amylyx Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 43 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 43

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

26% more call options, than puts

Call options by funds: $46.9M | Put options by funds: $37.2M

5% more funds holding

Funds holding: 147 → 154 (+7)

4.19% more ownership

Funds ownership: 77% → 81.19% (+4.2%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

22% less capital invested

Capital invested by funds: $1.51B → $1.18B (-$331M)

Holders
154
Holders Change
+7
Holders Change %
+4.76%
% of All Funds
2.42%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
29
Increased
66
Reduced
43
Closed
21
Calls
$46.9M
Puts
$37.2M
Net Calls
+$9.68M
Net Calls Change
-$15.3M

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$30.3M
2
Millennium Management
Millennium Management
New York
+$22.9M
3
Marshall Wace
Marshall Wace
United Kingdom
+$22.7M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$20.3M
5
EAM
Eventide Asset Management
Massachusetts
+$17.8M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$31.3M
2
DM
Deerfield Management
New York
-$25.2M
3
O
OrbiMed
New York
-$23.9M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$22.5M
5
ACA
Avoro Capital Advisors
New York
-$13.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
51
Ameriprise
Minnesota
$2.81M -$2.22M -82,281 -39%
Qube Research & Technologies (QRT)
52
Qube Research & Technologies (QRT)
United Kingdom
$2.68M +$2.5M +92,455 +291%
SCM
53
Soleus Capital Management
Connecticut
$2.59M +$1.53M +56,786 +90%
Bank of America
54
Bank of America
North Carolina
$2.53M +$1.32M +48,887 +72%
Voloridge Investment Management
55
Voloridge Investment Management
Florida
$2.47M -$563K -20,836 -15%
AA
56
AlphaCentric Advisors
Puerto Rico
$2.33M +$2.71M +100,500 +1,340%
TCM
57
Tekla Capital Management
Massachusetts
$2.24M +$2.81M +104,007 New
TCM
58
Tang Capital Management
California
$2.16M – – –
SFM
59
Sphera Funds Management
Israel
$2.16M +$2.7M +100,000 New
JGC
60
J. Goldman & Co
New York
$2.14M +$839K +31,062 +45%
OAM
61
Oberweis Asset Management
Illinois
$1.83M +$667K +24,695 +41%
Norges Bank
62
Norges Bank
Norway
$1.81M -$211K -7,800 -8%
Barclays
63
Barclays
United Kingdom
$1.68M -$106K -3,922 -5%
Citigroup
64
Citigroup
New York
$1.67M +$1.2M +44,443 +134%
PAMP
65
Polar Asset Management Partners
Ontario, Canada
$1.66M -$2.71M -100,200 -57%
UBS Group
66
UBS Group
Switzerland
$1.6M +$743K +27,522 +59%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$1.47M -$212K -7,867 -10%
Bank of Montreal
68
Bank of Montreal
Ontario, Canada
$1.42M +$1.6M +59,230 New
Swiss National Bank
69
Swiss National Bank
Switzerland
$1.41M +$1.77M +65,400 New
Tudor Investment Corp
70
Tudor Investment Corp
Connecticut
$1.29M +$596K +22,051 +59%
Wells Fargo
71
Wells Fargo
California
$1.24M +$960K +35,545 +162%
CIC
72
Cornercap Investment Counsel
Georgia
$1.21M +$1.52M +56,310 New
CSS
73
Cubist Systematic Strategies
Connecticut
$1.17M -$263K -9,750 -15%
First Trust Advisors
74
First Trust Advisors
Illinois
$1.17M +$724K +26,798 +98%
Walleye Capital
75
Walleye Capital
New York
$1.13M +$1.41M +52,378 New
1 2
3
4 5

AMLX Hedge Fund Activity: Q2 2023 in Review

154 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2023, worth a combined $1.18B — down 22% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new AMLX positions and 21 closed out — a net gain of 8 holders — while 66 added to existing stakes and 43 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $30.3M. The largest seller was Perceptive Advisors, cutting an estimated $31.3M.

  • 154 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2023, up from 147 in Q1 2023.
  • Funds reported $1.18B of Amylyx Pharmaceuticals stock for Q2 2023, down 22% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q2 2023 and 21 closed out, a net change of +8 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q2 2023 was Stonepine Capital Management, an estimated $30.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $31.3M sold.

Based on aggregated 13F filings for Q2 2023.